How to Cite
Abstract
A qualitative and quantitative immunohistochemical evaluation of expression of oncoprotein Bcl-2 in 140 patients with lung cancer (LC) was performed: 57 patients with paraneoplastic rheumatic syndrome (PNRS) and 83 — without symptoms of the syndrome. It was established that in the group of lung cancer patients with manifestations of PNRS the expression of Bcl-2 was rarely observed, and the average level of expression of Bcl-2 was much lower when compared to similar patients with lung cancer but without symptoms of the given syndrome. The presence of PNRS in patients with lung cancer leads to reduced tumor expression by Bcl-2, indicating a higher malignancy and aggressive nature of the tumors.References
Лактионов К.К., Давыдов М.И., Полоцкий Б.Е. и др. Прогностические и предсказывающие факторы у больных немелкоклеточным раком легкого // Практ. онкол. — 2006. — № 3. — С. 145-153.
Молекулярная диагностика опухолей: фундаментальные основы и практическое применение // Под ред. С.П. Осинского, Д.Ф. Глузмана, Й. Клиффа и др. — Киев: «ДІА». — 2007. — С. 248.
Руководство по иммуногистохимической диагностике опухолей человека // Под ред. С.В. Петрова, Н.Т. Райхлина. — Казань. — 2004. — С. 456.
Севостьянова Н.В., Малкова E.M., Чойнозов E.A и др. Особенности экспрессии молекулярно-биологических маркеров пролиферации и апоптоза у больных раком легкого // Бюлл. Сиб. Отд. РАМН. — 2004. — Т 112. — С. 49-53.
Соболева Ю.В. Сравнительный анализ взаимодействия процессов пролиферации, апоптоза и межкле точной адгезии при центральном и периферическом плоскоклеточном раке легкого // Тихоок. мед. журн. — 2009. — №. 1. — С. 33-34.
Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy // Oncogene. — 2007. — Vol. 26. — P. 1324-1337.
Brunelle J.K., Letai A. Control of mitochondrial apoptosis by the Bcl-2 family // J. Cell Sci. — 2009. — Vol. 122. — P. 437-441.
Chiappori A.A., Schreeder M.T., Moezi M.M. et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer // Br. J. Cancer. — 2012. — Vol. 106. — P. 839-845.
Gheita T.A., Ezzat Y, Sayed S. et al. Musculoskeletal manifestations in patients with malignant disease // Clin. Rheumatol. — 2010. — Vol. 29. — P. 181-188.
Hussein M.R. Alterations of p53 and Bcl-2 protein expression in the laryngeal intraepithelial neoplasia // Cancer Biol. Ther. — 2005. — Vol. 4. — P. 213-217.
Jesus G., Barcelos A., Neves C. et al. Rheumatic manifestations and neoplasms // J. Acta Reumatol. Port. — 2006. — Vol. 31. — P. 305-321.
Kang M.H., Reynolds C.P Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy // Clin. Cancer Res. — 2009. — Vol. 15. — P. 1126-1132.
Oki Y, Copeland A., Hagemeister F. et al. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma // Blood. — 2012. — Vol. 119. — P. 2171-2172.
Smilek P., Dusek L., Vesely K. et al. Correlation of expression of Ki-67, EGFR, cerbB-2, MMP-9, p53, bcl-2, CD34 and cell cycle analysis with survival in head and neck squamous cell cancer // J. Exp. Clin. Cancer Res. — 2006. — Vol. 25. — P. 549-555.
Weyhenmeyer B., Murphy A.C., Prehn J.H.M., Murphy B.M. Targeting the anti-apoptotic BCL-2 family members for the treatment of cancer // Exp. Oncol. — 2012. — Vol. 34. — P. 192-199.
Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death // Nat. Rev. Mol. Cell Biol. — 2008. — Vol. 9. — P. 47-59.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...